10-Q 1 ycbd_10q.htm QUARTERLY REPORT Blueprint
 
 

  UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 10-Q
 
(Mark One)
 
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2019
or
 
 
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ___________ to ___________
 
Commission file number    001-38299
 

cbdMD, INC.
(Exact Name of Registrant as Specified in its Charter)
 
North Carolina
 
47-3414576
State or Other Jurisdiction of Incorporation or Organization
 
I.R.S. Employer Identification No.
 
8845 Red Oak Blvd, Charlotte, NC
 
28217
Address of Principal Executive Offices
 
Zip Code
 
704-445-3060
Registrant’s Telephone Number, Including Area Code
 
 
4521 Sharon Rd, suite 450 Charlotte, NC 8211
Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
common
YCBD
NYSE American
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes      No ☐
 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes     No ☐
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
 
Large accelerated filer ☐
Accelerated filer ☐
Non-accelerated filer 
Smaller reporting company 
 
Emerging growth company 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).  Yes ☐    No  
 
APPLICABLE ONLY TO CORPORATE ISSUERS
 
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.
 
27,720,356 shares of common stock are issued and outstanding as of August 14, 2019
  

 
 
 
TABLE OF CONTENTS
 
 
OTHER PERTINENT INFORMATION
 
Unless the context otherwise indicates, when used in this report, the terms cbdMD,” “we,” “us, “our” and similar terms refer to cbdMD, Inc., a North Carolina corporation formerly known as Level Brands, Inc, and our subsidiaries CBD Industries, LLC, formally known as cbdMD LLC, a North Carolina limited liability company which we refer to as “CBDI”, Beauty and Pinups, LLC, a North Carolina limited liability company which we refer to as “BPU”, I | M 1, LLC, a California limited liability company, which we refer to as “I’M1”, Encore Endeavor 1 LLC, a California limited liability company which we refer to as “EE1” and Level H&W, LLC, a North Carolina limited liability company, which we refer to as “Level H&W”. In addition, “fiscal 2018" refers to the year ended September 30, 2018, "fiscal 2019" refers to the year ending September 30, 2019, "third quarter of 2018" refers to the three months ended June 30, 2018 and "third quarter of 2019" refers to the three months ended June 30, 2019.
 
The information contained on our websites at www.cbdmd.com, www.beautyandpinups.com, www.im1men.com, and www.encoreendeavor1.com are not part of this report.
 

 
2
 
 
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
 
This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Words such as, but not limited to, “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” “targets,” “likely,” “aim,” “will,” “would,” “could,” and similar expressions or phrases identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and future events and financial trends that we believe may affect our financial condition, results of operation, business strategy and financial needs. Forward-looking statements include, but are not limited to, statements about:
 
our ability to successfully integrate the operations of Cure Based Development following the Mergers;
 
our limited operating history;
 
the limited operating histories of our subsidiaries;
 
our history of losses;
the evolving and highly competitive market in which cbdMD operates;
the evolution of the laws and regulations impacting cbdMD
 
the terms of various agreements with kathy ireland® Worldwide and possible impacts on our management's abilities to make certain decisions regarding the operations of our Company;
 
our dependence on consumer spending patterns;
 
our history on reliance on sales from a limited number of customers, including related parties;
 
risks associated with our failure to effectively promote our brands;
 
our ability to identify and successfully acquire additional brands and trademarks;
 
the operating agreements of our I'M1 and EE1 subsidiaries;
 
the accounting treatment of securities we accept as partial compensation for services;
 
our ability to liquidate securities we accept as partial compensation for services;
 
the possible need to raise additional capital in the future;
 
terms of the contracts with third parties in each of our divisions;
 
possible conflicts of interest with kathy ireland® Worldwide;
 
possible litigation involving our licensed or manufactured products;
 
our ability to effectively compete and our dependence on market acceptance of our brands;
 
the lack of long-term contracts for the purchase of products from our products division;
 
our ability to protect our intellectual property;
 
additional operational risks associated with our products division;
 
risks associated with volatility in the market price of our common stock;
 
risks associated with any future failure to satisfy the NYSE American LLC continued listing standards;
 
dilution to our shareholders from the issuance of additional shares of common stock by us and/or the exercise of outstanding options and warrants;
 
risks associated with our status as an emerging growth company;
 
risks associated with control by our executive officers, directors and affiliates;
 
risks associated with our failure to maintain an effective system of internal control over financial reporting;
 
risks associated with unfavorable research reports; and
 
risks associated with our articles of incorporation, bylaws and North Carolina law.
 
Most of these factors are difficult to predict accurately and are generally beyond our control. You should consider the areas of risk described in connection with any forward-looking statements that may be made herein. Readers are cautioned not to place undue reliance on these forward-looking statements and readers should carefully review this report in its entirety, including the risks described in Part II, Item 1A. Risk Factors appearing later in this report, Part I, Item 1A. - Risk Factors in our Annual Report on Form 10-K for the fiscal year ended September 30, 2018 as filed with the Securities and Exchange Commission (the “SEC”) on December 12, 2018 (the "2018 10-K") and our Quarterly Report on Form 10-Q for the period ended March 31, 2019 as filed with the SEC on May 15, 2019 as well as our other filings with the SEC. Except for our ongoing obligations to disclose material information under the Federal securities laws, we undertake no obligation to release publicly any revisions to any forward-looking statements, to report events or to report the occurrence of unanticipated events.
  

 
3
 
 
PART 1 - FINANCIAL INFORMATION
 
ITEM 1.  FINANCIAL STATEMENTS.
 
cbdMD, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
JUNE 30, 2019 AND SEPTEMBER 30, 2018
 
 
 
(Unaudited)
 
 
 
 
 
 
June 30,
 
 
September 30,
 
 
 
2019
 
 
2018
 
Assets
 
 
 
 
 
 
 
 
 
 
 
 
 
Current assets:
 
 
 
 
 
 
  Cash and cash equivalents
 $11,633,213 
 $4,282,553 
  Accounts receivable
  562,800 
  307,874 
  Accounts receivable - related party
  1,103,628 
  1,537,863 
  Accounts receivable other
  276,795 
  1,743,874 
  Deposits
 6,850
 -
  Merchant reserve
  626,160 
  - 
  Marketable securities
  880,132 
  1,050,961 
  Investment other securities
  1,159,112 
  1,159,112 
  Note receivable
  486,000 
  459,000 
  Note receivable - related party
  - 
  156,147 
  Inventory
  3,116,458 
  123,223 
  Inventory prepaid
  643,649 
  - 
  Deferred issuance costs
  - 
  28,049 
  Prepaid consulting agreement
  - 
  200,000 
  Prepaid rent
  60,000 
  180,000 
  Prepaid services with stock
  198,000 
  - 
  Prepaid equipment - deposit
  889,673 
  - 
  Prepaid expenses and other current assets
  543,607 
  561,491 
Total current assets
  22,186,077 
  11,790,147 
 
    
    
Other assets:
    
    
  Property and equipment, net
  1,016,757 
  53,480 
  Goodwill
  55,133,697 
  - 
  Intangible assets, net
  22,572,097 
  3,173,985 
Total other assets
  78,722,551 
  3,227,465 
 
    
    
Total assets
 $100,908,628 
 $15,017,612 
 
See Notes to Condensed Consolidated Financial Statements
 
4
 
 
cbdMD, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
JUNE 30, 2019 AND SEPTEMBER 30, 2018
(continued)
  
 
 
 (Unaudited)
 
 
 
 
 
 
 June 30,
 
 
 September 30,
 
 
 
 2019
 
 
 2018
 
Liabilities and shareholders' equity
 
 
 
 
 
 
 
 
 
 
 
 
 
Current liabilities:
 
 
 
 
 
 
  Accounts payable
 $1,886,395 
 $473,717 
  Accounts payable - related party
  - 
  7,860 
  Deferred revenue
  4,585 
  161,458 
  Customer deposit - related party
  34,404 
  - 
  Accrued payroll
  326,537 
  - 
  Accrued expenses
  77,985 
  6,920 
  Accrued expenses - related party
  - 
  320,000 
Total current liabilities
  2,329,906 
  969,955 
 
    
    
Long term liabilities
    
    
  Other long term liabilities
  - 
  7,502 
  Contingent liability
  70,600,000 
  - 
  Deferred tax liability
  2,833,000 
  21,000 
Total long term liabilities
  73,433,000 
  28,502 
 
    
    
Total liabilities
  75,762,906 
  998,457 
 
    
    
cbdMD, Inc. shareholders' equity (deficit):
    
    
Preferred stock, authorized 50,000,000 shares, $0.001 par value, no shares issued and outstanding
  - 
  - 
Common stock, authorized 150,000,000 shares, $0.001 par value,
    
    
  27,720,356 and 8,123,928 shares issued and outstanding, respectively
  27,720 
  8,124 
Additional paid in capital
  96,130,158 
  21,781,095 
Accumulated other comprehensive income (loss)
  - 
  (2,512,539)
Accumulated deficit
  (70,782,736)
  (6,669,497)
Total cbdMD, Inc. shareholders' equity
  25,375,142 
  12,607,183 
Non-controlling interest
  (229,420)
  1,411,972 
Total shareholders' equity
  25,145,722 
  14,019,155 
 
    
    
Total liabilities and shareholders' equity
 $100,908,628 
 $15,017,612 
 
    
    
  
See Notes to Condensed Consolidated Financial Statements
 
5
 
 
cbdMD, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE AND NINE MONTHS ENDED JUNE 30, 2019 AND 2018
(Unaudited)
 
 
 
Three months
 
 
Three months
 
 
Nine months
 
 
Nine months
 
 
 
Ended
 
 
Ended
 
 
Ended
 
 
Ended
 
 
 
June 30,
2019
 
 
June 30,
2018
 
 
June 30,
2019
 
 
June 30,
2018
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sales
 $9,784,199 
 $1,851,116 
 $19,042,098 
 $5,440,653 
Sales related party
  - 
  1,350,000 
  - 
  1,550,000 
Total Gross Sales
  9,784,199 
  3,201,116 
  19,042,098 
  6,990,653 
 Allowances
  (1,739,863)
  (2,686)
  (4,075,381)
  (23,558)
    Net sales
  8,044,336 
  1,848,430 
  14,966,717 
  5,417,095 
  Net sales related party
  - 
  1,350,000 
  - 
  1,550,000 
Total Net Sales
  8,044,336 
  3,198,430 
  14,966,717 
  6,967,095 
   Cost of sales
  2,959,198 
  1,106,706 
  5,584,868 
  1,858,651 
 
    
    
    
    
   Gross Profit
  5,085,138 
  2,091,724 
  9,381,849 
  5,108,444 
 
    
    
    
    
Operating expenses excluding impairment losses
  11,230,914 
  1,464,239 
  18,680,857 
  4,089,006 
Impairment of intangible assets
  2,114,334 
  - 
  2,114,334 
  - 
     Operating expenses
  13,345,248 
  1,464,239 
  20,795,190 
  4,089,006 
  Income (Loss) from operations
  (8,260,110)
  627,485 
  (11,413,341)
  1,019,438 
    Realized and Unrealized gain (loss) on  marketable securities
  (497,451)
  - 
  (1,705,069)
  - 
     (Increase) of contingent liability
  (21,547,606)
  - 
  (52,461,680)
  - 
     Gain (loss) on disposal of property and equipment
  - 
  - 
  (34,333)
  (69,311)
   Interest income (expense)
  14,211 
  (232)
  76,330 
  (737)
  Income (loss) before provision for income taxes
  (30,290,956)
  627,253 
  (65,538,093)
  949,390 
 
    
    
    
    
  Benefit (Provision) for income taxes
  1,088,000 
  (62,000)
  2,296,000 
  (6,000)
   Net Income (Loss)
  (29,202,956)
  565,253 
  (63,242,093)
  943,390 
  Net Gain (Loss) attributable to noncontrolling interest
  (1,503,707)
  359,179 
  (1,641,391)
  465,848 
 
    
    
    
    
Net Income (Loss) attributable to cbdMD, Inc. common shareholders
 $(27,699,249)
 $206,074 
 $(61,600,702)
 $477,542 
 
    
    
    
    
Net Income (Loss) per share:
    
    
    
    
  Basic
 $(1.19)
 $0.03 
 $(4.22)
 $0.06 
  Diluted
 $- 
 $0.03 
 $- 
 $0.06 
 
    
    
    
    
 Weighted average number of shares Basic:
  23,193,793 
  8,075,341 
  14,585,619 
  7,614,621 
 Weighted average number of shares Diluted:
    
  8,092,931 
    
  7,637,012 
 
See Notes to Condensed Consolidated Financial Statements
 
6
 
 
cbdMD, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
FOR THE THREE AND NINE MONTHS ENDED JUNE 30, 2019 AND 2018
(Unaudited)
 
 
 
Three months
 
 
Three months
 
 
Nine months
 
 
Nine months
 
 
 
Ended
 
 
Ended
 
 
Ended
 
 
Ended
 
 
 
June 30,
2019
 
 
June 30,
2018
 
 
June 30,
2019
 
 
June 30,
2018
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net Income (Loss)
 $(29,202,956)
 $565,253 
 $(63,242,093)
 $943,390 
Other Comprehensive Income:
    
    
    
    
   Net Unrealized Gain (Loss) on Marketable Securities, net of tax
  - 
  (1,326,727)
  - 
  (1,923,304)
  Comprehensive Income (Loss)
  (29,202,956)
  (761,474)
  (63,242,093)
  (979,914)
 
    
    
    
    
Comprehensive Income (loss) attributable to non-controlling interest
  (1,503,707)
  359,179 
  (1,641,391)
  465,848 
Comprehensive Income (Loss) attributable to cbdMD, Inc. common shareholders
 $(27,699,249)
 $(1,120,653)
 $(61,600,702)
 $(1,445,762)
  
See Notes to Condensed Consolidated Financial Statements
 
7
 
 
cbdMD, INC.
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE NINE MONTHS ENDED JUNE 30, 2019 AND 2018
(unaudited)
 
 
 
Nine Months
Ended
June 30,
 
 
Nine Months
Ended
June 30,
 
 
 
2019
 
 
2018
 
Cash flows from operating activities:
 
 
 
 
 
 
Net loss
 $(63,242,093)
 $943,390 
Adjustments to reconcile net loss to net
    
    
  cash used by operating activities:
    
    
  Stock based compensation
  2,022,812 
  386,719 
  Restricted stock expense
  92,000 
  39,100 
  Issuance of stock / warrants for service
  289,750 
  478,002 
  Intangible impairment
  2,114,334 
  - 
  Inventory impairment
  - 
  102,124 
  Depreciation and amortization
  272,121 
  169,788 
  Gain on settlement of Note
  (20,000)
  - 
  Increase/(Decrease) in contingent liability
  52,461,680 
  - 
  Realized and unrealized loss of marketable securities
  1,705,069 
  - 
  Loss on sale of property and equipment
  - 
  69,311 
  Non-cash consideration received for services
  (470,000)
  (3,404,502)
Changes in operating assets and liabilities:
    
    
  Accounts receivable
  399,074 
  (45,502)
  Accounts receivable – related party
  204,902 
  (637,675)
  Other accounts receivable
  (298,754)
  (1,204,003)
  Other accounts receivable – related party
    
  236,364 
  Note receivable
  (27,000)
  (450,000)
  Note receivable – related party
  156,147 
  114,802 
  Merchant reserve
  (199,907)
  - 
  Inventory
  (2,581,958)
  10,340 
  Prepaid expenses and other current assets
  (717,894)
  (980,952)
  Marketable securities
  701,593 
  - 
  Accounts payable and accrued expenses
  1,073,211 
  (324,785)
  Accounts payable and accrued expenses – related party
  (313,591)
  (470,905)

    
    
  Deferred revenue / customer deposits
  (380,804)
  121,916 
  Deferred tax liability
  (2,296,000)
  6,000 
Cash used by operating activities
  (9,055,308)
  (4,840,368)
 
    
    
Cash flows from investing activities:
    
    
   Net cash used for merger
  (1,167,295)
  - 
   Purchase of investment other securities
  - 
  (300,000)
   Purchase of intangible assets
  (79,999)
  (360,000)
   Purchase of property and equipment
  (359,421)
  (2,465)
Cash used by investing activities
  (1,606,715)
  (662,465)
 
    
    
Cash flows from financing activities:
    
    
   Proceeds from issuance of common stock
  19,009,897 
  10,927,535 
Note Payable-related party
  (764,300)
  -
 
   Deferred issuance costs
  (232,914)
  (285,086)
Cash provided by financing activities
  18,012,683
  10,642,449 
Net increase (decrease) in cash
  7,350,660 
  5,139,616 
Cash and cash equivalents, beginning of period
  4,282,553 
  284,246 
Cash and cash equivalents, end of period
 $11,633,213 
 $5,423,862 
 
See Notes to Condensed Consolidated Financial Statements
 
8
 
 
cbdMD, INC.
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE NINE MONTHS ENDED JUNE 30, 2019 AND 2018
(unaudited) (continued)
 
Supplemental Disclosures of Cash Flow Information:
 
 
 
Nine Months
Ended
June 30,
 
 
Nine Months
Ended
June 30,
 
 
 
2019
 
 
2018
 
 
 
 
 
 
 
 
Cash Payments for:
 
 
 
 
 
 
    Interest expense
 $36,418
 $505 
 
    
    
Non-cash financial activities:
    
    
Warrants issued to secondary selling agent
 $309,592 
 $171,600 
Equity investment exchange to be issued in the future
 $- 
 $160,000 
Stock received for prior period services, adjusted for other accounts receivable write down prior to receipt
 $1,352,000 
 $- 
Adoption of ASU 2016-01
 $2,512,539 
 $- 
  
See Notes to Condensed Consolidated Financial Statements
 
9
 
 
cbdMD, INC.
CONSOLIDATED STATEMENT OF SHAREHOLDERS' (DEFICIT) EQUITY
FOR THE THREE AND NINE MONTHS ENDED JUNE 30, 2019
 
 
 
Common Stock
 
 
Additional Paid in
 
 
Other Comprehensive
 
 
Accumulated
 
 
Non-controlling
 
 
 
 
 
 
Shares
 
 
Amount
 
 
Capital
 
 
Income(loss)
 
 
Deficit
 
 
Interest
 
 
Total
 
Balance, September 30, 2018
  8,123,928 
  8,124 
  21,781,095 
  (2,512,539)
  (6,669,495)
  1,411,972 
  14,019,155 
Issuance of common stock
  1,971,428 
  1,971 
  6,355,027 
  - 
  - 
  - 
  6,356,998 
Issuance of options for share based compensation
  - 
  - 
  143,673 
  - 
  - 
  - 
  143,673 
Issuance of stock costs
  - 
  - 
  (205,569)
  - 
  - 
  - 
  (205,569)
Adoption of ASU 2016-01
  - 
  - 
  - 
  2,512,539 
  (2,512,539)
  - 
  - 
Net loss
  - 
  - 
  - 
  - 
  (2,109,715)
  (79,149)
  (2,188,864)
Balance, December 31, 2018
  10,095,356 
  10,095 
  28,074,224 
  - 
  (11,291,749)
  1,332,823 
  18,125,391 
Issuance of options for share based compensation
  - 
  - 
  19,475 
  - 
  - 
  - 
  19,475 
Issuance of stock and warrants for services
  75,000 
  75 
  289,675 
  - 
  - 
  - 
  289,750 
Net loss
  - 
  - 
  - 
  - 
  (31,791,738)
  (58,536)
  (31,850,274)
Balance, March 31, 2019
  10,170,356 
  10,170 
  28,383,374 
  - 
  (43,083,487)
  1,274,287 
  (13,415,658)
Issuance of common stock for merger
  15,250,000 
  15,250 
  53,199,913 
  - 
  - 
  - 
  53,215,163 
Issuance of common stock
  2,300,000 
  2,300 
  12,650,600 
  - 
  - 
  - 
  12,652,900 
Issuance of options for share based compensation
  - 
  - 
  1,859,664 
  - 
  - 
  - 
  1,859,664 
Issuance of stock costs
  - 
  - 
  (55,393)
  - 
  - 
  - 
  (55,393)
Issuance of stock and warrants for services
    
    
  92,000 
  - 
  - 
  - 
  92,000 
Net loss
  - 
  - 
  - 
  - 
  (27,699,249)
  (1,503,707)
  (29,202,956)
Balance, June 30, 2019
  27,720,356
  27,720 
  96,130,158 
  - 
  (70,782,736)
  (229,420)
  25,145,722 
  
See Notes to Condensed Consolidated Financial Statements
 
10
 
 
cbdMD, INC.
CONSOLIDATED STATEMENT OF SHAREHOLDERS' (DEFICIT) EQUITY
FOR THE THREE AND NINE MONTHS ENDED JUNE 30, 2018
 
 
 
Common Stock
 
 
Additional Paid in
 
 
Other Comprehensive
 
 
Accumulated
 
 
Non-controlling
 
 
 
 
 
 
Shares
 
 
Amount
 
 
Capital
 
 
Income(loss)
 
 
Deficit
 
 
Interest
 
 
Total
 
Balance, September 30, 2017
  5,792,261 
  5,792 
  10,463,480 
  - 
  (6,257,421)
  937,063 
  5,148,914 
Issuance of common stock
  2,000,000 
  2,000 
  9,971,114 
  - 
  - 
  - 
  9,973,114 
Issuance of options for share based compensation
  - 
  - 
  17,114 
  - 
  - 
  - 
  17,114 
Issuance of stock for deferred IPO costs
  - 
  - 
  171,600 
  - 
  - 
  - 
  171,600 
Issuance of stock and warrants for services
  6,667 
  7 
  36,995 
  - 
  - 
  - 
  37,002 
Issuance of restricted stock for share based compensation
  - 
  - 
  39,100 
  - 
  - 
  - 
  39,100 
Other Comprehensive income (loss)
  - 
  - 
  - 
  33,500 
  - 
  - 
  33,500 
Net loss
  - 
  - 
  - 
  - 
  (1,132,928)
  (131,855)
  (1,264,783)
Balance, December 31, 2017
  7,798,928 
  7,799 
  20,699,403 
  33,500 
  (7,390,349)
  805,208 
  14,155,561 
Issuance of common stock
  - 
  - 
  - 
  - 
  - 
  - 
  - 
Issuance of options for share based compensation
  - 
  - 
  13,952 
  - 
  - 
  - 
  13,952 
Issuance of stock and warrants for services
  235,000 
  235 
  19,765 
  - 
  - 
  - 
  20,000 
Other Comprehensive income (loss)
  - 
  - 
  - 
  (630,077)
  - 
  - 
  (630,077)
Net income
  - 
  - 
  - 
  - 
  1,404,397 
  238,523 
  1,642,920 
Balance, March 31, 2018
  8,033,928 
  8,034 
  20,733,120 
  (596,577)
  (5,985,952)
  1,043,731 
  15,202,356 
Issuance of options for share based compensation
  - 
  - 
  355,653 
  - 
  - 
  - 
  355,653 
Issuance of stock and warrants for services
  85,000 
  85 
  420,915 
  - 
  - 
  - 
  421,000 
Other Comprehensive income (loss)
  - 
  - 
  - 
  (1,326,727)
  - 
  - 
  (1,326,727)
Net income
  - 
  - 
  - 
  - 
  206,073 
  359,180 
  565,253 
Balance, June 30, 2018
  8,118,928 
  8,119 
  21,509,688 
  (1,923,304)
  (5,779,879)
  1,402,911 
  15,217,535 
  
See Notes to Condensed Consolidated Financial Statements
 
11
 
 
cbdMD , INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE NINE MONTHS ENDED JUNE 30, 2019 AND 2018
 
NOTE 1 – ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 
Organization and Nature of Business
 
cbdMD, Inc. ("cbdMD", "we", "us", “our”, "Parent Company” or the “Company”) is a North Carolina corporation formed on March 17, 2015 as Level Beauty Group, Inc. In November 2016 we changed the name of the Company to Level Brands, Inc. On April 22, 2019, following approval by our shareholders at the 2019 annual meeting held on April 19, 2019, we filed Articles of Amendment to our Articles of Incorporation changing the name of our Company to “cbdMD, Inc.” effective May 1, 2019. We operate from our offices located in Charlotte, North Carolina. Our fiscal year end is established as September 30.
 
The accompanying unaudited interim condensed consolidated financial statements of cbdMD have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules of the Securities and Exchange Commission (“SEC”) and should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company’s Annual Report filed with the SEC on Form 10-K for the year ended September 30, 2018 (“2018 10-K”). In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of consolidated financial position and the consolidated results of operations for the interim periods presented have been reflected herein. Notes to the financial statements which would substantially duplicate the disclosure contained in the audited consolidated financial statements for fiscal year 2018 as reported in the Form 10-K have been omitted.
 
In March 2015, the Company formed Beauty and Pin-Ups, LLC ("BPU"), a North Carolina limited liability company, and contributed $250,000 in exchange for our member interest. As of September 30, 2018, we own 100% interest in BPU. BPU’s initial business focus was to manufacture, market and sell an array of beauty and personal care products, including hair care and hair treatments, as well as beauty tools. The Company's products historically have been sold to the professional salon market, principally through distributors to professional salons in the North America and has expanded its focus to retailers, online segments and licensing opportunities. BPU no longer manufactures products and has focused on licensing agreements.
 
I’M1, LLC. (“I’M1”) was formed in California in September 2016. IM1 Holdings, LLC, a California limited liability company, (“IM1 Holdings”) was the initial member of I’M1. In January 2017, we acquired all of the Class A voting membership interests in I’M1 from IM1 Holdings in exchange for 583,000 shares of our common stock, which represents 51% of the interest in I’M1. IM1 Holdings continues to own the Class B non-voting membership interest of I’M1. I’M1 – Ireland Men One is a brand inspired by Kathy Ireland that focuses on providing millennial-inspired lifestyle products under the I’M1 brand. I’M1 has entered into an exclusive wholesale license agreement with kathy ireland® Worldwide in connection with the use of the intellectual property related to this brand.
 
Encore Endeavor 1, LLC (“EE1”) was formed in California in March 2016. EE1 Holdings, LLC, a California limited liability company, (“EE1 Holdings") was the initial member of EE1. In January 2017, we acquired all of the Class A voting membership interests in EE1 from EE1 Holdings in exchange for 283,000 shares of our common stock, which represents 51% of the interest in EE1. EE1 Holdings continues to own the Class B non-voting membership interests of EE1. EE1 is a brand management company and producer and marketer of multiple entertainment distribution platforms under the EE1 brand.
 
Level H&W, LLC (“Level H&W”) was formed in North Carolina in October 2017 and began operations in fiscal 2018; we own 100% interest in Level H&W. The Company signed an agreement with kathy ireland® Worldwide to retain exclusive rights to the intellectual property and other rights in connection with kathy ireland® Health & Wellness™ and its associated trademarks and tradenames. Level H&W focuses on establishing licensing arrangements under the kathy ireland® Health & Wellness™ brand.
 
On November 17, 2017, the Company completed an initial public offering (the “IPO”) of 2,000,000 shares of its common stock for aggregate gross proceeds of $12.0 million. The Company received approximately $10.9 million in net proceeds after deducting expenses and commissions. On October 2, 2018, the Company completed a secondary public offering of 1,971,428 shares of its common stock for aggregate gross proceeds of approximately $6.9 million. The Company received approximately $6.3 million in net proceeds after deducting underwriting discounts and commissions and other offering expenses payable by us. On May 15, 2019, the Company completed a secondary public offering of 2,300,000 shares of its common stock for aggregate gross proceeds of $13.8 million. The Company received approximately $12.5 million in net proceeds after deducting underwriting discounts and commissions and other estimated offering expenses payable by us.
 
 
12
 
 
On December 20, 2018 the Company, and its newly organized wholly-owned subsidiaries AcqCo, LLC and cbdMD LLC, completed a two-step merger (the “Mergers”) with Cure Based Development, LLC, a Nevada limited liability company (“Cure Based Development”). Upon completion of the Mergers, cbdMD LLC survived and operates the prior business of Cure Based Development. On April 10, 2019, cbdMD LLC was renamed to CBD Industries LLC (“CBDI”). As consideration for the Mergers, the Company had a contractual obligation, after approval by our shareholders, to issue 15,250,000 shares of our common stock to the members of Cure Based Development, of which 8,750,000 of the shares will vest over a five year period and are subject to a voting proxy agreement, as well as to issue another 15,250,000 shares of our common stock in the future upon earnout goals being within the next 5 years. The Company’s shareholders approved the issuance of the 15,250,000 shares of common stock and they were issued to members of Cure Based Development on April 19, 2019. CBDI produces and distributes various high-grade, premium cannibidiol oil (“CBD”) products under the cbdMD brand. CBD is a natural substance produced from the hemp plant and the products manufactured by CBDI are non pyschoactive as they do not contain tetrahydrocannibinol (THC).
 
Principles of Consolidation
 
The consolidated financial statements include the accounts of the Company and its majority owned subsidiaries I’M1 and EE1 and wholly owned subsidiaries CBDI, BPU and Level H&W. All material intercompany transactions and balances have been eliminated in consolidation. The third party ownership of the Company’s subsidiaries is accounted for as non-controlling interest in the consolidated financial statements. Changes in the non-controlling interest are reported in the statement of shareholders’ equity (deficit).
 
Use of Estimates
 
The preparation of the Company's consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”), and requires management to make estimates and assumptions that affect amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the financial statements and reported amounts of revenues and expenses during the periods presented. Estimates and assumptions are reviewed periodically and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary. Significant estimates made in the accompanying consolidated financial statements include, but are not limited to, allowances for doubtful accounts, inventory valuation reserves, expected sales returns and allowances, trade support costs, certain assumptions related to the valuation of investments other securities, marketable securities, common stock, acquired intangible and long-lived assets and the recoverability of intangible and long-lived assets and income taxes, including deferred tax valuation allowances and reserves for estimated tax liabilities, contingent liability and, hence consideration for the Mergers is a material estimate. Actual results could differ from these estimates.
 
Cash and Cash Equivalents
 
For financial statements purposes, the Company considers all highly liquid investments with a maturity of less than three months when purchased to be cash equivalents.
 
Accounts receivable and Accounts receivable other
 
Accounts receivable are stated at cost less an allowance for doubtful accounts, if applicable. Credit is extended to customers after an evaluation of the customer’s financial condition, and generally collateral is not required as a condition of credit extension. Management’s determination of the allowance for doubtful accounts is based on an evaluation of the receivables, past experience, current economic conditions, and other risks inherent in the receivables portfolio. As of June 30, 2019, we have an allowance for doubtful accounts of $14,689, and had no allowance at September 30, 2018.
 
In addition, the Company may, from time to time, enter into contracts where a portion of the consideration provided by the customer in exchange for the Company's services is common stock, options or warrants (an equity position).  In these situations, upon invoicing the customer for the stock or other instruments, the Company will record the receivable as accounts receivable other, and use the value of the stock or other instrument upon invoicing to determine the value. Where an accounts receivable is settled with the receipt of the common stock or other instrument, the common stock or other instrument will be classified as an asset on the balance sheet as either a marketable security (when the customer is a publicly traded entity) or as an investment other security (when the customer is a private entity). 
 
 
13
 
 
Accounts receivable and accounts receivable other items that involve a related party are indicated as such on the face of the financial statements.
 
Receivable and Merchant Reserve
 
The Company primarily sells its products through the internet and has an arrangement to process customer payments with third-party payment processors. The arrangement with the payment processors requires that the Company pay a fee between 5.95% - 6.95% of the transaction amounts processed. Pursuant to this agreement, there is a waiting period between 2 - 14 days prior to reimbursement to the Company, as well as a calculated reserve which the payment processor holds back. Fees and reserves can change periodically with notice from the processors. At June 30, 2019, the receivable from payment processors included approximately $205,761 for the waiting period amount and is recorded as accounts receivable in the accompanying consolidated balance sheet and $626,160 for the reserve amount for a total receivable of $831,921.
 
Marketable Securities
 
Marketable securities that are equity securities are carried at fair value on the consolidated balance sheets with changes in fair value recorded as an unrealized gain or (loss) in the Statements of Operations in the period of the change. Upon the disposition of a marketable security, the Company records a realized gain or (loss) on the Company’s consolidated statements of operations.  On October 1, 2018, as a result of the adoption of ASU 2016-01 – Financial Instruments, the Company reclassified $2,512,539 of net unrealized losses on marketable securities, that were formerly classified as available-for-sale securities before the adoption of the new standard, from Accumulated Other Comprehensive Loss to Accumulated Deficit.
 
Investment Other Securities
 
For equity investments where the Company neither controls nor has significant influence over the investee and which are non-marketable, which is without a readily determinable fair value, the Company may elect to estimate its fair value at cost less impairment plus or minus changes resulting from observable price changes.
 
Inventory
 
Inventory is stated at the lower of cost or net realizable value with cost being determined on a weighted average basis. The cost of inventory includes product cost, freight-in, and production fill and labor (portions of which we outsource to third party manufacturers). Write-offs of potentially slow moving or damaged inventory are recorded based on management’s analysis of inventory levels, forecasted future sales volume and pricing and through specific identification of obsolete or damaged products. We assess inventory quarterly for slow moving products and potential impairments and at a minimum perform a physical inventory count annually near fiscal year end.
 
Customer Deposits
 
Customer deposits consist of payments received in advance of revenue recognition. Revenue is recognized as revenue recognition criteria are met.
 
Property and Equipment
 
Property and equipment items are stated at cost less accumulated depreciation. Expenditures for maintenance and repairs are charged to operating expense as incurred. Depreciation is charged to expense over the estimated useful lives of the assets using the straight-line method. Generally, the useful lives are five years for show booths and equipment, three to four years for manufacturer’s molds and plates, computers, furniture and equipment, leasehold improvements, and software. The cost and accumulated depreciation of property are eliminated from the accounts upon disposal, and any resulting gain or loss is included in the consolidated statement of operations for the applicable period. Long-lived assets held and used by the Company are reviewed for impairment whenever changes in circumstance indicate the carrying value of an asset may not be recoverable.
 
 
14
 
 
Fair value accounting 
 
The Company utilizes accounting standards for fair value, which include the definition of fair value, the framework for measuring fair value, and disclosures about fair value measurements. Fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, fair value accounting standards establish a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels 1 and 2 of the hierarchy) and the reporting entity’s own assumptions about market participant assumptions (unobservable inputs classified within Level 3 of the hierarchy).
 
Level 1 inputs utilize quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Level 2 inputs are inputs other than quoted prices included in Level 1 that are directly or indirectly observable for the asset or liability. Level 2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability. Level 3 inputs are unobservable inputs for the asset or liability, which are based on an entity’s own assumptions, as there is little, if any, observable market activity. In instances where the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.
 
When the Company records an investment in marketable securities the carrying value is assigned at fair value.  Any changes in fair value for marketable securities during a given period will be recorded as an unrealized gain or loss in the consolidated statement of operations. For investment other securities without a readily determinable fair value, the Company may elect to estimate its fair value at cost less impairment plus or minus changes resulting from observable price changes.
 
Intangible Assets
 
The Company's intangible assets consist of trademarks, goodwill, and other intellectual property, which are accounted for in accordance with ASC Topic 350, Intangibles – Goodwill and Other. The Company employs the non-amortization approach to account for purchased intangible assets having indefinite lives. Under the non-amortization approach, intangible assets having indefinite lives are not amortized into the results of operations, but instead are reviewed annually or more frequently if events or changes in circumstances indicate that the assets might be impaired, to assess whether their fair value exceeds their carrying value. We perform an impairment analysis at August 1 annually on the indefinite-lived intangible assets following the steps laid out in ASC 350-30-35-18. Our annual impairment analysis includes a qualitative assessment to determine if it is necessary to perform the quantitative impairment test. In performing a qualitative assessment, we review events and circumstances that could affect the significant inputs used to determine if the fair value is less than the carrying value of the intangible assets. If a quantitative analysis is necessary, we would analyze various aspects including number of contracts acquired and retained as well as revenues from those contracts, associated with the intangible assets. In addition, intangible assets will be tested on an interim basis if an event or circumstance indicates that it is more likely than not that an impairment loss has been incurred.
 
Intangible assets with finite useful lives are amortized using the straight-line method over their estimated period of benefit. In accordance with ASC 360-10-35-21, finite lived intangibles are reviewed annually, or more frequently if events or changes in circumstances indicate that the assets might be impaired, to assess whether their fair value exceeds their carrying value.
 
In conjunction with any acquisitions, the Company refers to ASC-805 as amended by Accounting Standards Update (“ASU”) 2017-01 in determining if the Company is acquiring any inputs, processes or outputs and the impact that such factors would have on the classification of the acquisition as a business combination or an asset purchase. Additionally, the Company refers to the aforementioned guidance in reviewing all acquired assets and assumed liabilities for valuation in a business combination, including the determination of intangible asset values.
 
Contingent liability
 
A significant component of the purchase price consideration for the Company’s acquisition of Cure Based Development includes a fixed number of future shares to be issued as well as a variable number of future shares to be issued based upon the post-acquisition entity reaching certain specified future revenue targets, as further described in Note 8. The Company made a determination of the fair value of the contingent liabilities as part of the valuation of the assets acquired and liabilities assumed in the business combination.
 
 
15
 
 
The Company recognizes both the fixed number of shares to be issued, and the variable number of shares to be potentially issued, as contingent liabilities on its Consolidated Balance Sheets. These contingent liabilities are recorded at fair value upon the acquisition date and are remeasured quarterly based on the reassessed fair value as of the end of that quarterly reporting period.
 
For the three months ended June 30, 2019, the contingent liabilities associated with the business combination were increased by $21,547,606 to reflect their reassessed fair values as of June 30, 2019. This increase is reflective of a change in value from march 31, 2019 of the fixed shares issued on April 19, 2019, and the variable number of shares on June 30, 2019. Additionally, as the fixed shares were issued on April 19, 2019, the value of the shares in the amount of $53,215,163 was reclassified from the contingent liability to additional paid in capital on the balance sheet. For the three months ended June 30, 2019, the Company made no material adjustments to the forecasted performance of the post-acquisition entity that would impact the estimated likelihood that the revenue targets disclosed in Note 8 would be met. The primary catalyst for the $21,547,606 increase in contingent liabilities is the change in the Company’s share price between March 31, 2019 and June 30, 2019. These increases or reductions to the contingent liabilities are reflected within Other Expenses on the consolidated statements of operations.
 
Revenue Recognition
 
The Company adopted ASC 606, Revenue from Contracts with Customers using the modified retrospective method beginning with our quarter ending December 31, 2018. The adoption of the new revenue standards as of October 1, 2018 did not change the Company’s revenue recognition as the majority of its revenues continue to be recognized when the customer takes control of its product, the services have been rendered, or the usage-based royalty has been earned. As the Company did not identify any accounting changes that impacted the amount of reported revenues with respect to any of its revenue streams, no adjustment to retained earnings was required upon adoption.
 
Under the ASC 606, the Company recognizes revenues when its customer obtains control of promised goods or services, in an amount that reflects the consideration which it expects to receive in exchange for those goods. The Company recognizes revenues following the five step model prescribed under ASC 606: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation.
 
Performance Obligations
 
A performance obligation is a promise in a contract to transfer a distinct good or service to a customer. The Company has reviewed its various revenue streams for its existing contracts under the five-step approach. The Company has entered into various license agreements that provide revenues based on guarantee minimum royalty payments with additional royalty revenues based on a percentage of defined sales. Guaranteed minimum royalty payments (fixed revenue) are recognized on a straight-line basis over the term of the contract, as defined in each license agreement. Earned royalties and earned royalties in excess of the fixed revenue (variable revenue) are recognized as income during the period corresponding to the licensee’s sales. Earned royalties in excess of fixed revenue are only recognized when the Company is reasonably certain that the guaranteed minimums payments for the period will be exceeded.
 
The below table summarizes amounts related to future performance obligations under fixed contractual arrangements as of June 30, 2019:
 
 
 
Remainder of fiscal 2019
 
 
2020 and thereafter
 
 
 
 
 
 
 
 
Future performance obligations
 $0 
 $0 
 
Allocation of transaction price
 
At times, the Company enters into contracts with customers wherein there are multiple elements that may have disparate revenue recognition patterns. In such instances, the Company must allocate the total transaction price to these various elements. This is achieved by estimating the standalone selling price of each element, which is the price at which we sell a promised good or service separately to a customer.
 
 
16
 
 
In circumstances where we have not historically sold relevant products or services on a standalone basis, the Company utilizes the most situationally appropriate method of estimating standalone selling price. These methods include (i) an adjusted market assessment approach, wherein we refer to prices from our competitors for similar goods or serves and adjust those prices as necessary to reflect our typical costs and margins, (ii) an expected cost plus margin approach, wherein we forecast the costs that we will incur in satisfying the identified performance obligation and adding an appropriate margin to such costs, and (iii) a residual approach, wherein we adjust the total transaction price to remove all observable standalone selling prices of other goods or services included in the contract and allocate the entirety of the remaining contract amount to the remaining obligation.
 
Revenue recognition
 
The Company records revenue from the sale of its products when risk of loss and title to the product are transferred to the customer, which is upon shipping. Net sales are comprised of gross revenues less product returns, trade discounts and customer allowances, which include costs associated with off-invoice mark-downs and other price reductions, as well as trade promotions. These incentive costs are recognized at the later of the date on which the Company recognizes the related revenue or the date on which the Company offers the incentive. Although currently the Company does not have a formal return policy and historically our returns have been immaterial, in connection with the Mergers with Cure Based Development we are evaluating implementation of a formal refund/return policy.
 
The Company also enters into various license agreements that provide revenues based on royalties as a percentage of sales and advertising/marketing fees. The contracts can also have a minimum royalty, with which this and the advertising/marketing revenue is recognized on a straight-line basis over the term of each contract year, as defined, in each license agreement. Royalties exceeding the defined minimum amounts are recognized as income during the period corresponding to the licensee’s sales, as are all royalties that do not have a minimum royalty. Payments received as consideration of the grant of a license are recognized ratably as revenue over the term of the license agreement and are reflected on the Company’s consolidated balance sheets as deferred revenue at the time payment is received and recognized ratably as revenue over the term of the license agreement.  Similarly, advanced royalty payments are recognized ratably over the period indicated by the terms of the license and are reflected in the Company’s consolidated balance sheet in deferred revenue at the time the payment is received.  Revenue is not recognized unless collectability is reasonably assured. If licensing arrangements are terminated prior to the original licensing period, we will recognize revenue for any contractual termination fees, unless such amounts are deemed non-recoverable. Licensing for trademarks are considered symbolic, which contain the characteristics of a right-to-access license since the customer is simultaneously receiving the intellectual property and benefiting from it throughout the license period. As such, the Company primarily records revenue from licenses on a straight-line basis over the license period as the performance obligation is satisfied over time.
 
In regard to sales for services provided, the Company records revenue when the customer has accepted services and the Company has a right to payment. Based on the contracted services, revenue is recognized when the Company invoices customers for completed services at agreed upon rates or revenue is recognized over a fixed period of time during which the service is performed. 
 
Disaggregated Revenue
 
Our segment reporting categorizes Company activity into the following broad transaction types: product sales, licensing arrangements and advisory services. We believe that these segment categories appropriately reflect how the nature, amount, timing and uncertainty of revenue and cash flows are impacted by economic factors. See Note 14 – Segment Information, for disaggregated presentation of revenue.
 
Contract Balances
 
Contract assets represent unbilled receivables and are presented within accounts receivable, net on the condensed consolidated balance sheets. Contract liabilities represent unearned revenues and are presented as deferred revenue or customer deposits on the condensed consolidated balance sheets.
 
 
17
 
 
The below table summarize the net change in contract assets and contract liabilities from October 1, 2018 to June 30, 2019:
 
 
 
Entertainment
 
 
Products
 
 
Licensing
 
 
Total
 
Balance at September 30, 2018
 $37,500 
  - 
 $115,625 
 $153,125 
Billed during three months ended December 31, 2018
  75,000 
  265,000 
  - 
  340,000 
Earned during three months ended December 31, 2018
  (68,750)
  - 
  (115,625)
  (184,375)
Balance at December 31, 2018
 $43,750 
 $265,000 
  - 
 $308,750 
Amount returned during three months ended March 31, 2019
    
  (175,000)
    
  (175,000)
Billed during three months ended March 31, 2019
  - 
  - 
  10,000 
  10,000 
Earned during three months ended March 31, 2019
  (18,750)
  - 
  (1,667)
  (20,417)
Balance at March 31, 2019
 $25,000 
 $90,000 
 $8,333 
 $123,333 
Billed during three months ended June 30, 2019
  - 
  - 
  - 
  - 
Earned during three months ended June 30, 2019
  (18,750)
  (55,596)
  (1,667)
  (76,013)
Balance at June 30, 2019
 $6,250 
 $34,404 
 $6,666 
 $47,320 
 
Cost of Sales
 
Our cost of sales includes costs associated with distribution, fill and labor expense, components, manufacturing overhead, and outbound freight for our products division, and includes labor, third-party service providers, and amortization expense related to intellectual property for our licensing and entertainment divisions. In our products division, cost of sales also includes the cost of refurbishing products returned by customers that will be offered for resale and the cost of inventory write-downs associated with adjustments of held inventories to their net realizable value. These expenses are reflected in the Company’s consolidated statements of operations when the product is sold and net sales revenues are recognized or, in the case of inventory write-downs, when circumstances indicate that the carrying value of inventories is in excess of their net realizable value.
 
Advertising Costs
 
The Company expenses all costs of advertising and related marketing and promotional costs as incurred. The Company incurred approximately $2,604,000 and $443,000 in advertising and related marketing and promotional costs included in operating expenses during the three months ended June 30, 2019 and 2018, respectively. The Company incurred approximately $4,411,000 and $1,036,000 in advertising and related marketing and promotional costs included in operating expenses during the nine months ended June 30, 2019 and 2018, respectively.
 
Shipping and Handling Fees and Costs
 
All fees billed to customers for shipping and handling are classified as a component of sales. All costs associated with shipping and handling are classified as a component of cost of goods sold.
 
 
18
 
 
Income Taxes
 
The Parent Company is a North Carolina corporation that is treated as a corporation for federal and state income tax purposes. Prior to April 2017, BPU was a multi-member limited liability company that was treated as a partnership for federal and state income tax purposes. As such, the Parent Company’s partnership share in the taxable income or loss of BPU was included in the tax return of the Parent Company. Beginning in April 2017, the Parent Company acquired the remaining interests in BPU. As a result of the acquisition, BPU became a disregarded entity for tax purposes and its entire share of taxable income or loss was included in the tax return of the Parent Company. CBDI and Level H&W are wholly owned subsidiaries and are disregarded entities for tax purposes and their entire share of taxable income or loss is included in the tax return of the Parent Company. IM1 and EE1 are multi-member limited liability companies that are treated as partnerships for federal and state income tax purposes. As such, the Parent Company’s partnership share in the taxable income or loss of IM1 and EE1 are included in the tax return of the Parent Company.
 
The Parent Company accounts for income taxes pursuant to the provisions of the Accounting for Income Taxes topic of the FASB ASC 740 which requires, among other things, an asset and liability approach to calculating deferred income taxes. The asset and liability approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. The Parent Company uses the inside basis approach to determine deferred tax assets and liabilities associated with its investment in a consolidated pass-through entity. A valuation allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net deferred asset will not be realized. US GAAP requires management to evaluate tax positions taken by the Company and recognize a tax liability (or asset) if the Company has taken an uncertain tax position that more likely than not would not be sustained upon examination by the Internal Revenue Service. Management has analyzed the tax positions taken by the Company, and has concluded that as of June 30, 2019 and 2018, there were no uncertain tax positions taken or expected to be taken that would require recognition of a liability (or asset) or disclosure in the consolidated financial statements.
 
Concentrations
 
Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents, accounts receivable, and securities.
 
The Company places its cash and cash equivalents on deposit with financial institutions in the United States. The Federal Deposit Insurance Corporation (“FDIC”) covers $250,000 for substantially all depository accounts. The Company from time to time may have amounts on deposit in excess of the insured limits. The Company had a $10,007,079 uninsured balance at June 30, 2019 and a $0 uninsured balance at September 30, 2018. Funds which are not subject to coverage or loss under FDIC were $7,577 and $4,003,003 at June 30, 2019 and September 30, 2018, respectively.
 
Concentration of credit risk with respect to receivables is principally limited to trade receivables with corporate customers that meet specific credit policies. Management considers these customer receivables to represent normal business risk. The Company did not have any customers that represented a significant amount of our sales for the three and nine months ended June 30, 2019, respectively. The Company had sales to three customers that collectively represented approximately 89% and 80% of total net sales for the three and nine months ended June 30, 2018, respectively. The aggregate accounts receivable of such customers represented approximately 83% of the Company’s total accounts receivable and a long term note receivable at June 30, 2018.
 
Stock-Based Compensation
 
We account for our stock compensation under the ASC 718-10-30, Compensation - Stock Compensation using the fair value based method. Under this method, compensation cost is measured at the grant date based on the value of the award and is recognized over the service period, which is usually the vesting period. This guidance establishes standards for the accounting for transactions in which an entity exchanges its equity instruments for goods or services. It also addresses transactions in which an entity incurs liabilities in exchange for goods or services that are based on the fair value of the entity's equity instruments or that may be settled by the issuance of those equity instruments.
 
We use the Black-Scholes model for measuring the fair value of options and warrants. The stock based fair value compensation is determined as of the date of the grant or the date at which the performance of the services is completed (measurement date) and is recognized over the vesting periods. Under ASU 2016-09 which amends ASC 718, which became effective October 1, 2017, we elected to change our accounting policy to recognize forfeitures when they occur. This change had no impact on beginning retained earnings as there had been no forfeitures estimated or incurred in prior periods.
 
 
19
 
 
Net Income (Loss) Per Share
 
The Company uses ASC 260-10, Earnings Per Share for calculating the basic and diluted income (loss) per share. The Company computes basic income (loss) per share by dividing net income (loss) and net income (loss) attributable to common shareholders by the weighted average number of common shares outstanding. Common equivalent shares are excluded from the computation of net loss per share if their effect is anti-dilutive.
 
At the three and nine months ended June 30, 2019, 1,623,255 shares that will be potentially issued in the future were excluded from the shares used to calculate diluted loss per share as their inclusion would reduce net loss per share.
 
New Accounting Standards
 
In May 2014, August 2015 and May 2016, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, and ASU 2015-14 Revenue from Contracts with Customers, Deferral of the Effective Date, respectively, which implement ASC Topic 606. ASC Topic 606 outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance under US GAAP, including industry-specific guidance. It also requires entities to disclose both quantitative and qualitative information that enable financial statements users to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Subsequently, the FASB has issued the following standards related to ASU 2014-09: ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (“ASU 2016-08”); ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing (“ASU 2016-10”); ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients (“ASU 2016-12”); and ASU No. 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers (“ASU 2016-20”). The amendments in these ASUs are effective for annual periods beginning after December 15, 2017, and interim periods therein. Early adoption is permitted for annual periods beginning after December 15, 2016. These ASUs may be applied retrospectively to all prior periods presented, or retrospectively with a cumulative adjustment to retained earnings in the year of adoption. The new revenue standards became effective for the Company on October 1, 2018 and were adopted using the modified retrospective method. The adoption of the new revenue standards as of October 1, 2018 did not change the Company’s revenue recognition as the majority of its revenues continue to be recognized when the customer takes control of its product, the services have been rendered, or the royalty has been received. As the Company did not identify any accounting changes that impacted the amount of reported revenues with respect to its product revenues, no adjustment to retained earnings was required upon adoption.
 
In February 2016, the FASB issued ASU 2016-02, Leases.  The purpose of ASU 2016-02 is to establish the principles to report transparent and economically neutral information about the assets and liabilities that arise from leases. This guidance results in a more faithful representation of the rights and obligations arising from operating and capital leases by requiring lessees to recognize the lease assets and lease liabilities that arise from leases in the statement of financial position and to disclose qualitative and quantitative information about lease transactions, such as information about variable lease payments and options to renew and terminate leases. ASU 2016-02 is effective for fiscal years and interim periods beginning after December 15, 2018. The Company does have a 3 year lease for a manufacturing facility and is assessing the impact of implementing this guidance on its consolidated financial position, results of operations and liquidity.
 
In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820). The ASU modifies, removes, and adds several disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement. The ASU 2018-13 is effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted upon issuance of ASU 2018-13. An entity is permitted to early adopt any removed or modified disclosures upon issuance of ASU 2018-13 and delay adoption of the additional disclosures until their effective date. The Company is evaluating the effect ASU 2018-13 will have on its consolidated financial statements and disclosures and has not yet determined the effect of the standard on its ongoing financial reporting at this time.
 
 
20
 
 
NOTE 2 – ACQUISITIONS
 
On December 20, 2018 (the “Closing”), the Company, and its newly organized wholly-owned subsidiaries AcqCo, LLC and cbdMD LLC, both North Carolina limited liability companies, completed a two-step merger (the “Merger Agreement”) with Cure Based Development, LLC, a Nevada limited liability company (“Cure Based Development”). The Merger Agreement provided that AcqCo LLC merge with and into Cure Based Development with Cure Based Development as the surviving entity (the “Merger”), and immediately thereafter Cure Based Development merged with and into cbdMD LLC with cbdMD LLC as the surviving entity (the “Secondary Merger” and collectively with the Merger, the “Mergers”). cbdMD LLC was renamed on April 10, 2019 to CBD Industries LLC and has continued as a wholly-owned subsidiary of the Company and maintains the operations of Cure Based Development pre-closing. As consideration for the Merger, the Company has a contractual obligation, after approval by our shareholders, to issue 15,250,000 shares of our common stock to the members of Cure Based Development, of which 8,750,000 of the shares will vest over a five year period and are subject to a voting proxy agreement. The Merger Agreement also provides that an additional 15,250,000 shares of our common stock can be issued upon the satisfaction of aggregate net revenue criteria by CBDI, within 60 months following the Closing. The net revenue criteria are: $20.0, $40.0, $80.0 and $160.0 million, in aggregate $300.0 million (See Note 8 for more information).
 
The initial 15,250,000 shares were approved by our shareholders and issued on April 19, 2019.
 
The Company owns 100% of the equity interest of CBDI. The valuation and purchase price allocation for the Mergers remains preliminary and will be finalized by September 30, 2019.
 
During the three months ended March 31, 2019, the Company identified equipment that was improperly excluded from the identified assets acquired in the Mergers. The fair value of this equipment was determined to be $114,275. The purchase price allocation was adjusted by increasing Property and equipment, net and reducing Goodwill by this amount.
 
During the three months ended June 30, 2019, the Company identified interest overly accrued valued at $10,572 that was in the initial purchase price allocation. The purchase price allocation was adjusted by decreasing goodwill and accrued expenses by this amount.
 
The following table presents the preliminary purchase price allocation:
 
Consideration
 $74,353,483 
 
    
Assets acquired:
    
   Cash and cash equivalents
 $1,822,331 
   Accounts receivable
  850,921 
   Inventory
  1,054,926 
   Other current assets
  38,745 
   Property and equipment, net
  723,223 
   Intangible assets
  21,585,000 
   Goodwill
  55,133,697 
Total assets acquired
  81,208,843 
 
    
Liabilities assumed:
    
   Accounts payable
  257,081 
   Notes payable – related party
  764,300 
   Customer deposits - related party
  265,000 
   Accrued expenses
  460,979 
   Deferred tax liability
  5,108,000 
Total Liabilities assumed
  6,855,360 
 
    
Net Assets Acquired
 $74,353,483 
 
The goodwill generated from this transaction can be attributed to the benefits the Company expects to realize from the growth strategies the acquired Company had developed and the entry into an emerging market with high growth potential. See Note 8 regarding contingent liability.
 
 
21
 
 
In connection with the purchase price allocation, the Company recorded a deferred tax liability of approximately $5,108,000, with a corresponding increase to goodwill, for the tax effect of the acquired intangible assets from Cure Base Development. This liability was recorded as there will be no future tax deductions related to the acquired intangibles, and we have identified these as indefinite-lived intangible assets.
 
The Company also acquired estimated net operating loss carryforwards of approximately $1,996,000, Under Internal Revenue Code (IRC) Section 382, the use of net operating loss (“NOL”) carryforwards may be limited if a change in ownership of a company occurs.
 
NOTE 3 – MARKETABLE SECURITIES AND INVESTMENT OTHER SECURITIES
 
The Company may, from time to time, enter into contracts where a portion of the consideration provided by the customer in exchange for the Company's services is common stock, options or warrants (an equity position).  In these situations, upon invoicing the customer for the stock or other instruments, the Company will record the receivable as accounts receivable other, and use the value of the stock or other instrument upon invoicing to determine the value. If there is insufficient data to support the valuation of the security directly, the Company will value it, and the underlying revenue, using the estimated fair value of the services provided. Where an accounts receivable is settled with the receipt of the common stock or other instrument, the common stock or other instrument will be classified as an asset on the balance sheet as either a marketable security (when the customer is a public entity) or as an investment other security (when the customer is a private entity). 
 
On June 23, 2017, I’M1 and EE1 in aggregate exercised a warrant for 1,600,000 shares of common stock for services delivered to a customer and accounted for this in Investment other securities. The common stock was issued to the Company’s subsidiaries I’M1 and EE1. The customer is a private entity and the stock was valued at $912,000, which was based on its recent financing in June 2017 at $0.57 per share. The Company has classified this common stock as Level 3 for fair value measurement purposes as there are no observable inputs. In valuing the stock the Company used the fair value of the services provided, utilizing an analysis of vendor specific objective evidence of its selling price. In August 2017, each of I’M1 and EE1 distributed the shares to its majority owner, cbdMD, and also distributed shares valued at $223,440 to its non-controlling interests. In August 2017, the Company also provided referral services for kathy Ireland® Worldwide and this customer. As compensation the Company received an additional 200,000 shares of common stock valued at $114,000 using the pricing described above. The Company assessed the investment and determined there was not an impairment for the period ended June 30, 2019.
 
On September 19, 2017, I’M1 and EE1 in aggregate exercised a warrant for 56,552 shares of common stock for services delivered to a customer and accounted for this in Investment other securities. The common stock was issued to the Company’s subsidiaries I’M1 and EE1. The customer is a private entity and the stock was valued at $56,552, which was based on all 2017 financing transactions of the customer set at $1.00 per share, with the most recent third party transaction in August 2017. The Company has classified this common stock as Level 3 for fair value measurement purposes as there are no observable inputs. In valuing the stock the Company used factors including financial projections provided by the issuer and conversations with the issuer management regarding the Company’s recent results and future plans and the Company’s financing transactions over the past twelve months. The Company assessed the investment and determined there was not an impairment for the period ended June 30, 2019.
 
In November 2017, the Company completed services in relation to an agreement with SG Blocks, Inc. (NASDAQ: SGBX). As payment for these services, SG Blocks issued 50,000 shares of its common stock to the Company. The customer is a publicly traded entity and the stock was valued based on the trading price at the day the services were determined delivered, which was $5.09 per share for an aggregate value of $254,500. The Company determined that this common stock was classified as Level 1 for fair value measurement purposes as the stock was actively traded on an exchange. From November 7, 2018 thru December 13, 2018, the Company sold the 50,000 shares held and recorded a realized loss on marketable securities of $25,673 as of December 31, 2018 in the consolidated statement of operations. The Company no longer has this equity position.
 
In December 2017, the Company completed services per an advisory services agreement with Kure Corp, formerly a related party. As payment for these services, Kure Corp issued 800,000 shares of its stock to the Company. The customer was a private entity and the stock was valued at $400,000, which was based on financing activities by Kure Corp in September 2017 in which shares were valued at $0.50 per share. The Company had classified this common stock, cumulative value of $400,000, as Level 3 for fair value measurement purposes as there were no observable inputs. In valuing the stock the Company used factors including information provided by the issuer regarding their recent results and future plans as well as their most recent financing transactions. On April 30, 2018, Kure Corp. merged with Isodiol International, Inc. (CSE: ISOL, OTCQB: ISOLF, FSE:LB6A.F), a Canadian company. Details can be reviewed in our Form 10-K previously filed. As a result of this merger we received the first issuance of 380,952 shares from Isodiol and valued them based on the trading price on April 30, 2018 of $0.63 per share which totaled $240,000. We also removed the value of the Kure equity of $400,000 from our Level 3 investments as part of the exchange described above. As the full value of the Kure equity will not be received until the future issuances based on earn out goals, we have recorded an accounts receivable other of $160,000 as of December 31, 2018. On March 31, 2019, Isodiol spun off Kure to its original shareholders by issuing back all original Kure stock. As a result of the spin off, the Company will receive 800,000 shares of Kure stock valued at $160,000 and as Kure is private, the shares will be treated as a Level 3 stock and will be accounted for against the $160,000 accounts receivable other. The Company has determined that the 800,000 shares have a fair market value over $160,000. The Company has assessed the common stock and determined there was not an indication of an impairment at June 30, 2019.
 
 
22
 
 
On December 21, 2017, the Company purchased 300 shares of preferred stock in a private offering from a prior customer for $300,000. The preferred shares are convertible into common stock at a 20% discount of a defined subsequent financing, or an IPO offering of a minimum $15 million, or at a company valuation of $45 million whichever is the least. The customer is a private entity. The Company has classified this common stock as Level 3 for fair value measurement purposes as there are no observable inputs. In valuing the stock the Company used the value paid, which was the price offered to all third party investors. As of June 30, 2019, the Company has determined there is no impairment on the value of the shares of stock.
 
On December 30, 2017 the Company entered into an Agreement with Isodiol International, Inc. (CSE: ISOL, OTCQB: ISOLF, FSE:LB6A.F), a Canadian company which is a developer of pharmaceutical grade phytochemical compounds and a manufacturer and developer of phytoceutical consumer products. As payment for these services, the Company has received 1,226,435 shares of Isodiol common stock between December 31, 2017 and January 2019. The Company also received 38,095 shares of Isodiol stock upon Isodiol’s acquisition of Kure Corp, giving the Company a total of 1,264,530 shares. At June 30, 2019, the Company has 1,042,193 shares valued at $880,132.
 
On June 26, 2018 the Company entered into an Agreement with Boston Therapeutics, Inc. (OTC: BTHE), a pharmaceutical company focused on the development, manufacturing and commercialization of novel compounds to address unmet medical needs in diabetes. The agreement involved a licensing agreement and required the Company to create IP for a branding / marketing campaign. As payment for these services, Boston Therapeutics agreed to pay $850,000, of which $450,000 was issued as a note due no later than December 31, 2019 and $400,000 to be paid thru the issuance of BTI common stock based on the trading price at the agreement date ($0.075). As the stock has not been issued, we have recorded an unrealized gain (loss) of $(106,667) and ($293,333) for the three and nine month periods ended June 30, 2019, respectively based on a trading price of $0.02 at June 30, 2019. At June 30, 2019, the carrying value is $106,667.
 
The table below summarizes the assets valued at fair value as of June 30, 2019:
 
 
 
In Active Markets for Identical Assets and Liabilities
(Level 1)
 
 
Significant Other Observable Inputs
 (Level 2)
 
 
  Significant Unobservable Inputs
 (Level 3)
 
 
  Total Fair Value at
June 30,
2019
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Marketable securities
 $880,132 
  - 
 $- 
 $880,132 
Investment other securities
  - 
  - 
 $1,159,112 
 $1,159,112 
 
 
 
Level 1
 
 
Level 2
 
 
Level 3
 
 
Total
 
Balance at September 30, 2018
 $1,050,961 
 $- 
 $1,159,112 
 $2,210,073 
Sale of equities
 $(200,000)
 $- 
 $- 
 $(200,000)
Change in value of equities
 $(132,303)
 $- 
 $- 
 $(132,303)
Balance at December 31, 2018
 $718,658 
 $- 
 $1,159,112 
 $1,877,770 
Sale of equities
 $(103,998)
 $- 
 $- 
 $(103,998)
Receipt of equity investment upon completion of services
 $470,000 
 $- 
 $- 
 $470,000 
Change in value of equities
 $288,473 
 $- 
 $- 
 $288,473 
Balance at March 31, 2019
 $1,373,133 
 $- 
 $1,159,112 
 $2,532,245 
Sale of equities
 $(132,924)
 $- 
 $- 
 $(132,924)
Change in value of equities
 $(360,077)
 $- 
 $- 
 $(360,077)
Balance at June 30, 2019
 $880,132 
 $- 
 $1,159,112 
 $2,039,244 
 
 
23
 
 
NOTE 4 – INVENTORY
 
Inventory at June 30, 2019 and September 30, 2018 consists of the following:
 
 
 
June 30,
 
 
September 30,
 
 
 
2019
 
 
2018
 
Finished goods
 $1,665,037 
 $18,531 
Inventory components
  1,451,420 
  104,692 
Inventory prepaid
  643,649 
  - 
Total
 $3,760,107 
 $123,223 
 
At March 31, 2019, the Company determined that inventory related to BPU was impaired by approximately $139,217, as the BPU inventory balance was adjusted to zero as we no longer manufacture or intend to sell BPU products. During the year ended September 30, 2018, the Company determined that inventory was impaired by approximately $262,000. Impairment charges were recorded within operating expenses for the respective periods.
 
NOTE 5 – PROPERTY AND EQUIPMENT
 
Major classes of property and equipment at June 30, 2019 and September 30, 2018 consist of the following:
 
 
 
June 30,
 
 
September 30,
 
 
 
2019
 
 
2018
 
Computers, furniture and equipment
 $39,927 
 $59,770 
Show booth and equipment
  - 
  49,123 
Manufacturing equipment
  822,691 
  - 
Leasehold improvements
  269,591 
  - 
Automobiles
  24,892 
  - 
Manufactures’ molds and plates
  - 
  34,200 
 
  1,157,101 
  143,093 
Less accumulated depreciation
  (140,344)
  (89,613)
Net property and equipment
 $1,016,757 
 $53,480 
 
Depreciation expense related to property and equipment was $57,874 and $8,443 for the three months ended June 30, 2019 and 2018, respectively. Depreciation expense related to property and equipment was $119,566 and $30,757 for the nine months ended June 30, 2019 and 2018, respectively.
 
NOTE 6 – INTANGIBLE ASSETS
 
With the Mergers of Cure Based Development, the Company has made a strategic shift toward the CBD business and all entities and their associated intangibles were being assessed during the three months ended June 30, 2019 with that focus and their ability to support that business line.
 
On April 13, 2015, BPU acquired from BPUNY certain assets, including the trademark "Beauty & Pin Ups" and its variants and certain other intellectual property and assumed $277,500 of BPUNY's accounts payable to its product vendor, which was paid off in April 2016. At June 30, 2019, the Company recorded an impairment charge for the full carrying value of $234,422 (see below).
 
On January 6, 2017, the Company acquired 51% ownership in I’M1 from I’M1 Holdings. I’M1’s assets include the trademark "I’M1” and its variants and certain other intellectual property. Specifically, a licensing agreement with kathy ireland® Worldwide and an advisory agreement for services with kathy ireland® Worldwide. The licensing agreement provides the rights to use of the tradename for business and licensing purposes, this is the baseline of the business and will be required as long as the business is operating. The rights associated with this licensing agreement have been identified as indefinite-lived intangible assets. At June 30, 2019, the Company recorded an impairment charge for the full carrying value of $971,667 (see below).
 
 
24
 
 
On January 6, 2017, the Company acquired 51% ownership in EE1 from EE1 Holdings. EE1’s assets include the trademark "EE1” and its variants and certain other intellectual property. Specifically, a production deal agreement with BMG Rights Management US and an advisory agreement for services with kathy ireland® Worldwide. The rights associated with these agreements have been identified as indefinite-lived intangible assets. At June 30, 2019, the Company recorded an impairment charge for the full carrying value of $471,667 (see below).
 
On September 8, 2017, the Company entered into a seven year wholesale license agreement with Andre Carthen and issued 45,500 shares of common stock, valued at $179,725. In addition, the Company agreed to pay $65,000 in cash within 30 days completion of its initial public offering and also issued warrants to purchase 45,500 shares of common stock at a strike price of $4.00. The warrants were valued at $65,338. Under the terms of this nonexclusive agreement, we have the right to use, assign and sublicense the marks, intellectual property and other rights in connection with "Chef Andre," "Andre Carthen," ACafe" or "Fit Chef" and all trade names, trademarks and service marks related to this intellectual property for the purpose of entering into sublicense agreements with third parties for the manufacture, marketing and sale of products utilizing these marks. In December 2018, the parties amended the agreement to remove the annual minimum guarantee in return for a one time payment of $70,000. We are amortizing the capitalized value of the cash, warrants and common stock over the seven year term of the agreement and have amortized $0 and $11,073 for the three months ended June 30, 2019 and 2018, respectively, and have amortized $26,205 and $33,219 for the nine months ended June 30, 2019 and 2018, respectively. As of June 30, 2019, the Company recorded an impairment charge for the full carrying value of $296,460 (see below).
 
On September 8, 2017, the Company entered into a seven year wholesale license agreement with Nicholas Walker and issued 25,000 shares of common stock, valued at $98,750. In addition, the Company agreed to pay $40,000 in cash within 30 days completion of its initial public offering and also issued warrants to purchase 25,000 shares of common stock at a strike price of $4.00. The warrants were valued at $35,900. Under the terms of this nonexclusive agreement, we have the right to use, assign and sublicense the marks, intellectual property and other rights in connection with "Jardin," "Nicholas Walker," "Nicholas Walker Jardin," "Nicholas Walker Garden Party," "Cultivated by Nicholas Walker," and "Jardin Du Jour," and all trade names, trademarks and service marks related to this intellectual property for the purpose of entering into sublicense agreements with third parties for the manufacture, marketing and sale of products utilizing these marks. In December 2018, the parties amended the agreement to remove the annual minimum guarantee in return for a one time payment of $10,000. We are amortizing the capitalized value of the cash, warrants and common stock over the seven year term of the agreement and have amortized $0 and $6,237 for the three months ended June 30, 2019 and 2018, respectively, and have amortized $13,055 and $18,712 for the nine months ended June 30, 2019 and 2018, respectively. As of June 30, 2019, the Company recorded an impairment charge for the full carrying value of $140,118 (see below).
 
In September 2017, the Company entered into an exclusive seven year license agreement with kathy ireland® Worldwide for the right to license the mark, intellectual property and other marks in connection with kathy ireland® Health & Wellness™. The agreement is for seven years for a license fee of $840,000. The Company has an option to extend for another three years for an additional price of $360,000. Per the agreement, $480,000 was paid prior to January 1, 2018. The remaining amount of $360,000 was due in equal installments on January 1 of subsequent years until the license fee is paid. Under this license agreement with kathy ireland® Worldwide we were granted an exclusive, royalty free right to license, assign and use the kathy ireland® Health & Wellness™ trademark, and all trade names, trademarks and service marks related to the intellectual property including any derivatives or modifications, goodwill associated with this intellectual property when used in conjunction with health and wellness as well as Ms. Ireland's likeness, videos, photographs and other visual representations connected with kathy ireland® Health & Wellness™. In January 2018, the Company amended its wholesale license agreement with kathy Ireland® Worldwide. The amendment accounted for the Company exercising its option on a three year extension and amending the payment terms related to this extension as follows: royalty payments to kathy ireland® Worldwide for the three year extension would be set at 35% of net proceeds, to pay $400,000 within 5 days of executing the amendment (which was paid on January 31, 2018), and to pay the final amounts due under the Agreement, $320,000, on the latter of January 1, 2019 or 30 days after the receipt by the Company of $5,000,000 in net proceeds from sublicense agreements signed under the health and wellness trademarks. On December 20, 2018, both parties agreed to reduce the final amount owed to $300,000 if paid within 5 days, which was paid immediately. We are amortizing the asset over the ten year term of the agreement and have amortized $29,032 and $27,097 for the three months ended June 30, 2019 and 2018, respectively, and have amortized $87,096 and $57,096 for the nine months ended June 30, 2019 and 2018, respectively.
 
On December 20, 2018, the Company completed the Mergers with Cure Based Development and acquired certain assets, including the trademark "cbdMD" and its variants and certain other intellectual property. The trademark is the cornerstone of this subsidiary and is key as we create and distribute products and continue to build this brand. We believe the trademark does not have limits on the time it will contribute to the generation of cash flows and therefore we have identified these as indefinite-lived intangible assets (see Note 2 for more information).
 
 
25
 
 
Intangible assets as of June 30, 2019 and September 30, 2018 consisted of the following:
 
 
 
June 30,
 
 
September 30,
 
 
 
2019
 
 
2018
 
Trademark and other intellectual property related to I’M1
 $- 
 $971,667 
Trademark and other intellectual property related to EE1
  - 
  471,667 
Trademark and other intellectual property related to cbdMD
  21,585,000 
  - 
Trademark, tradename and other intellectual property related to kathy ireland® Health & Wellness™, net
  987,097 
  1,074,194 
Wholesale license agreement with Chef Andre Carthen, net
  - 
  262,077 
Wholesale license agreement with Nicholas Walker, net
  - 
  147,620 
Trademark and other intellectual property related to BPU
  - 
  246,760 
Total
 $22,572,097 
 $3,173,985 
 
The Company has one definite lived intangible asset, which has a ten year life.
 
Future amortization schedule:
 
Intangible
 
Total unamortized cost
 
 
2019
 
 
2020
 
 
2021
 
 
2022
 
 
2023
 
 
thereafter
 
Trademark, tradename and other intellectual property related to kathy ireland® Health & Wellness™
 $987,097 
 $29,033 
 $116,129 
 $116,129 
 $116,129 
 $116,129 
 $493,548 
 
The Company performs an impairment analysis at August 1 annually on the indefinite-lived intangible assets following the guidance in ASC 350-30-35-18. Our annual impairment analysis includes a qualitative assessment to determine if it is necessary to perform the quantitative impairment test. In performing a qualitative assessment, we review events and circumstances that could affect the significant inputs used to determine if the fair value is less than the carrying value of the intangible assets. In addition, intangible assets will be tested on an interim basis if an event or circumstance indicates that it is more likely than not that an impairment loss has been incurred and the Company evaluates the indefinite-lived intangible assets each reporting period to determine whether events and circumstances continue to support an indefinite useful life. The Company performed a qualitative analysis during the three months ended June 30, 2019. As the business focus of the Company has shifted to the CBD business, all other subsidiaries were being assessed to determine how they can support the CBD business. Therefore, the brand management and men’s lifestyle businesses will not continue to function as they have historically and the intangible assets (trademarks, logos, etc.) will not be used to promote and build the business as they have in the past, thus we have determined that a full impairment was required. As a result, the Company recorded an impairment charge during the three months ended June 30, 2019 for the indefinite-lived intangible assets of $471,667 under EE1 and an impairment charge of $971,667 under I’M1, respectively.
 
The Company performed a qualitative and quantitative analysis for the year ended September 30, 2018 accounting for the performance of BPU and the business shift in relation to its original business model and current focus on licensing and determined that an impairment was required. As a result, the Company recorded an impairment charge of $240,000 as impairment to intangibles under the BPU segment for the year ended of September 30, 2018. No other impairments were identified. Based upon the anticipated changes to BPU’s business model, the Company had determined that it was appropriate to reclassify the remaining carrying value of this intangible asset to a definite-lived asset. The Company began amortizing this asset beginning the first quarter of 2019. This reclassification was accounted for as a prospective change in estimate.
 
The Company also performs an impairment analysis at August 1 annually on the definite lived intangible assets following the guidance in ASC 360-10-35-21. We first assess if there is an indicator of possible impairment such as change in the use of the asset, market price changes in the asset, or other events that impact the value of the asset. If an indicator is present we then perform a quantitative analysis to determine if the carrying amount of the asset is recoverable. This is done by comparing the total undiscounted future cash flows of the long-lived asset to its carrying amount. If the total undiscounted future cash flows exceed the carrying amount of the asset, the carrying amount is deemed recoverable and an impairment is not recorded. If the carrying amount of a long-lived asset is deemed to be unrecoverable, an impairment loss needs to be estimated.
 
 
26
 
 
As previously indicated, the Company has made a strategic shift toward the CBD business and all entities were being assessed during the three months ended June 30, 2019 with that focus and their ability to support that business line. As such the definite lived intangible assets for BPU as well as the two wholesale license agreements with Nicolas Walker and Andre Carthen do not fit into the strategic direction and the value associated with future cash flows as it relates to these assets may not be positive. As a result, the Company recorded an impairment charge during the three months ended June 30, 2019 for the definite lived intangible assets of $234,422 for the BPU trademark/logo, and $296,460 and $140,118 for the two wholesale license agreements.
 
In order to calculate the impairment loss, the fair value of the asset must be determined. Fair value referenced here is determined using the guidance in FASB ASC Topic 820. .
 
NOTE 7 – PRO FORMA FINANCIAL INFORMATION (UNAUDITED)
 
The following unaudited pro-forma data summarizes the results of operations for the three and nine months ended June 30, 2019 and 2018, as if the Mergers with Cure Based Development had been completed on October 1, 2017. The pro-forma financial information is presented for informational purposes only and is not indicative of the results of operations that would have been achieved if the Mergers had taken place on October 1, 2017.
 
 
 
Three Months Ended
June 30,
2019
 
 
Three Months Ended
June 30,
2018
 
 
 
 
 
 
 
 
Net sales
 $N/A* 
 $4,817,417 
Operating income (loss)
 $N/A* 
 $1,011,470 
Net income (loss)
 $N/A* 
 $949,470 
Net income per share – average weighted shares
 $N/A* 
 $0.04 
Net income per share – fully diluted
 $N/A* 
 $0.04 
  
 
 
Nine Months Ended
June 30,
2019
 
 
Nine Months Ended
June 30,
2018
 
 
 
 
 
 
 
 
Net sales
 $18,050,145 
 $9,167,212 
Operating income (loss)
 $(12,614,392)
 $1,172,901 
Net income (loss)
 $(64,501,470)
 $1,166,901 
Net income (loss) per share – average weighted shares
 $(2.78)
 $0.05 
Net income per share – fully diluted
 $  
 $0.05 
 
* All entities were consolidated effective December 21, 2018 therefore, the results of operations are included in these condensed financial statements.
 
For the per share calculation prior to April 2019, it is being assumed that the shares to be issued contractually under the Merger Agreement, upon shareholder approval, were issued at the beginning of each period. This would account for an additional 6,500,000 shares issued directly to the members of Cure Based Development and another 8,750,000 shares issued which would have a voting proxy and leak out on voting rights over a 5 year period.
 
NOTE 8 – CONTINGENT LIABILITY
 
As consideration for the Mergers, described in Note 2, the Company has a contractual obligation to issue 15,250,000 shares of our common stock, after approval by our shareholders, to the members of Cure Based Development, issued in two tranches 6,500,000 and 8,750,000, both of which are subject to leak out provisions, and the 8,750,000 tranche of shares will also vest over a five year period and are subject to a voting proxy agreement. The Merger Agreement also provides that an additional 15,250,000 shares of our common stock can be issued upon the satisfaction of certain aggregate net revenue criteria by cbdMD within 60 months following the Closing Date (“earn out”).
 
 
27
 
 
The contractual obligations and earn out provision are accounted for as a contingent liability and fair value is determined using Level 3 inputs, as estimating the fair value of these contingent liabilities require the use of significant and subjective inputs that may and are likely to change over the duration of the liabilities with related changes in internal and external market factors.
 
The initial two tranches totaling 15,250,000 shares have been valued using a market approach method and included the use of the following inputs: share price upon contractual obligation, discount for lack of marketability to address leak out restrictions, and probability of shareholder disapproval. In addition, the 8,750,000 shares in the second tranche also included an input for a discount for lack of voting rights during the vest periods.
 
The Merger Agreement also provides that an additional 15,250,000 shares (Earnout Shares) would be issued as part of the consideration for the Mergers, upon the satisfaction of certain aggregate net revenue criteria by cbdMD within 60 months following the Closing Date as follows, as measured at four intervals (Marking Period): the completion of 12, 24, 42, and 59 calendar months from the Closing Date, and based upon the ratios set forth below:
 
Aggregate Net Revenues
 
Shares Issued / Each $ of Aggregate Net Revenue Ratio
 
 
 
 
 
  $1 - $20,000,000 
  .190625 
  $20,000,001 - $60,000,000 
  .0953125 
  $60,000,001 - $140,000,000 
  .04765625 
  $140,000,001 - $300,000,000 
  .023828125 
 
For clarification purposes, the Aggregate Net Revenues during a Marking Period shall be multiplied by the applicable Shares Issued/Each $ of Aggregate Net Revenue Ratio, minus, the number of shares issued as a result of Aggregate Net Revenues during the prior Marking Periods.
 
The initial 15,250,000 shares and Earnout Shares were approved by our shareholders and the initial shares were issued on April 19, 2019.
 
The 15,250,000 Earnout Shares which would be issued in the future, upon the satisfaction of net revenue criteria have been valued using a Monte Carlo Simulation. Inputs used included: stock price, volatility, interest rates, revenue projections, and likelihood of obtaining revenue projections, amongst others.
 
The value of the contingent liability was $102,267,557 at March 31, 2019 and was comprised of $50,842,557 for the initial 15,250,000 shares and $51,425,000 for the Earnout Shares. The initial shares were issued upon shareholder approval on April 19, 2019 and, therefore, that component of the contingent liability was revalued as of that date. The value of the initial shares as of April 19, 2019 was $53,215,163 and the increase of $2,372,606 is recorded in the Statement of Operations for the three months ended June 30, 2019. Additionally, as the 15,250,000 initial shares were issued on April 19, 2019, the value of the shares in the amount of $53,215,163 was reclassified from the contingent liability to additional paid in capital on the balance sheet. The Earnout Shares were valued at $70,600,000 on June 30, 2019 as compared to $51,425,000 at March 31, 2019. The increase of $19,175,000 is recorded in the Statement of Operations for the three months ended June 30, 2019. The Company utilized both a market approach and a Monte Carlo simulation in valuing the contingent liability and a key input in both of those methods is the stock price. The main driver of the increase in the value of the Earnout Shares within the contingent liability was the increase of the Company’s stock price, which was $5.90 at June 30, 2019 as compared to $4.42 on March 31, 2019.
 
NOTE 9 – RELATED PARTY TRANSACTIONS
 
On July 31, 2017, the Company sold preferred shares it had received from a customer as payment for services to a related party. The preferred shares were originally valued as marketable securities at $650,000 and were sold for $475,000, an approximation of fair market value, which was paid $200,000 in cash and a short term note of $275,000 at 3% interest, which is included in note receivable related party as of September 30, 2018. The short term note was extended on August 1, 2018, and the outstanding principal of $155,400 at 5% interest was paid in full on November 15, 2018.
 
 
28
 
 
On August 1, 2017, the Company entered into an additional advisory agreement with Kure Corp., then a related party, in which the Company would act as an advisor regarding business strategy involving (1) conversion of Kure franchises into company stores, (2) conversion of Kure Corp. debt and preferred shares into common share of Kure Corp. and (3) preparation steps required and a strategy to position for a possible Reg A+ offering. The services are to be delivered in two phases, the first deliverables of items 1 and 2 above were delivered by September 30, 2017 and item 3 was delivered by June 30, 2018. The Company was paid $200,000 in Kure Corp. stock for the first deliverables and was paid $145,500 in cash for the second deliverable.
 
On September 8, 2017, the Company extended its Master Advisory and Consulting Agreement, executed in February 2017, with kathy ireland® Worldwide to February 2025.
 
In September 2017, the Company entered into an exclusive seven year wholesale license agreement with kathy ireland® Worldwide for the right to license the mark, intellectual property and other marks in connection with kathy ireland® Health & Wellness™. The agreement is for seven years for a license fee of $840,000. The Company has an option to extend for another three years for an additional price of $360,000. Per the agreement, $480,000 was paid prior to January 1, 2018. The remaining amount of $360,000 are due in equal installments on January 1 of subsequent years until the license fee is paid. Under this license agreement with kathy ireland® Worldwide we were granted an exclusive, royalty free right to license, assign and use the kathy ireland® Health & Wellness™ trademark, and all trade names, trademarks and service marks related to the intellectual property including any derivatives or modifications, goodwill associated with this intellectual property when used in conjunction with health and wellness as well as Ms. Ireland's likeness, videos, photographs and other visual representations connected with kathy ireland® Health & Wellness™. Royalties are paid at 33 1/3% of net proceeds with the license fee being a credit against royalties. On January 30, 2018, the Company amended its wholesale license agreement with kathy Ireland® Worldwide. The amendment accounted for the Company exercising its option on a three year extension and amending the payment terms related to this extension as follows: royalty payments to kathy ireland® Worldwide for the three year extension would be set at 35% of net proceeds, to pay $400,000 within 5 days of executing the amendment (which was paid on January 31, 2018), and to pay the final amounts due under the agreement, $320,000 on the latter of January 1, 2019 or 30 days after the receipt by the Company of $5,000,000 in net proceeds from sublicense agreements signed under the health and wellness trademarks. On December 20, 2018, both parties agreed to reduce the final amount owed to $300,000 if paid within 5 days, which was paid immediately.
 
On December 11, 2017, the Company entered into a service agreement with Kure Corp., then a related party, to facilitate the “Vape Pod” transaction with the modular building systems vendor, SG Blocks, Inc., which is also a customer of our Company. Under the terms of this agreement we also agreed to facilitate the introduction to third parties in connection with Kure Corp.'s initiative to establish Vape Pod's at U.S. military base retail locations and advising and aid in site selection for Kure retail stores on military bases and adjoining convenience stores, gas stations, and other similar retail properties utilizing Kure Corp.'s retail Vape Pod concept, among other services. As compensation for this recent agreement, we were issued 400,000 shares of Kure Corp.'s common stock which was valued at $200,000 (see Note 3 Marketable Securities and Other Investment Securities).
 
In June 2018, per our agreement with kathy ireland® Worldwide, the Company earned a referral fee of $150,000 for facilitating a business opportunity which led to a new license agreement for kathy ireland® Worldwide. The Company is to receive 50% of all royalty revenue earned ongoing via the new business contract.
 
In April 2018 through June 2018, EE1 engaged in five separate statements of work for various marketing campaigns, production processes, and documentary related services for Sandbox LLC. Under the terms of the agreements, EE1 earned in the range of $200,000 to $250,000 for each statement of work, from Sandbox LLC. Sandbox LLC is an affiliate of a former member of our board of directors.
 
In September 2018, B&B Bandwidth purchased products from our subsidiary BPU for resale. The total purchase was $332,985. B&B Bandwidth management are affiliates of kathy ireland® Worldwide.
 
On December 20, 2018, with the closing of the Merger Agreement with Cure Based Development, we recognized the following related party transactions which happened prior to the Mergers:
 
Cure Based Development has received $90,000 from Verdure Holdings LLC for future orders of the Company’s products. Verdure Holdings LLC is an affiliate of the CEO of Cure Based Development. This amount is recorded as customer deposits - related party on the accompanying balance sheet.
 
 
29
 
 
Cure Based Development entered a lease for office space, which also provides administrative and IT services, from an affiliate of the CEO of Cure Based Development. The lease is a month to month lease for $9,166 per month.
 
Cure Based Development leases its manufacturing facility from an entity partially owned by an individual who now has a contractual right to receive shares of the Company as part of the Mergers. The current lease was entered into on December 15, 2018 and is for three years at an annual base rent rate of $151,200 allowing for a 3% annual increase. In addition, common area maintenance rent is set at $25,200 annually.
 
As we engage in providing services to customers, at times we will utilize related parties, typically as a part of our agreement with kathy ireland® Worldwide, to assist in delivery of the services. For the three months ended June 30, 2019 and 2018 we incurred related party cost of sales of approximately $0 and $745,000, respectively. For the nine months ended June 30, 2019, and 2018 we incurred related party cost of sales of approximately $161,500 and $1,228,000, respectively
 
NOTE 10 – SHAREHOLDERS’ EQUITY
 
Preferred Stock – We are authorized to issue 50,000,000 shares of preferred stock, par value $0.001 per share. Our preferred stock does not have any preference, liquidation, or dividend provisions. No shares of preferred stock have been issued.
 
Common Stock – We are authorized to issue 150,000,000 shares of common stock, par value $0.001 per share. There were 27,720,356 and 8,123,928 shares of common stock issued and outstanding at June 30, 2019 and September 30, 2018, respectively.
 
Common stock transactions:
 
In the three and nine months ended June 30, 2019:
 
On October 2, 2018, the Company completed a secondary public offering of 1,971,428 shares of its common stock for aggregate gross proceeds of approximately $6.9 million. The Company received approximately $6.3 million in net proceeds after deducting underwriting discounts and commissions and other estimated offering expenses payable by us. The Company also issued to the selling agent warrants to purchase in aggregate 51,429 shares of common stock with an exercise price of $4.375. The warrants were valued at $86,092 and expire on September 28, 2023.
 
In January 2019, we issued 25,000 shares of our common stock to an investment banking firm for general financial advisory services. The shares were valued at $77,250, based on the trading price upon issuance, and is being amortized and expensed as professional services over the service period ending December 2019.
 
In January 2019, we issued 50,000 shares of our common stock to an investment banking firm for general advisory and investment bank services. The shares were valued at $212,500, based on the trading price upon issuance, and is being amortized and expensed as professional services over the service period ending April 2020.
 
In April 2019, we issued 15,250,000 shares or our common stock as consideration for the Mergers with Cure Based Development, of which 8,750,000 of the shares will vest over a five year period and are subject to a voting proxy agreement.
 
In May 2019, the Company completed a secondary public offering of 2,300,000 shares of its common stock for aggregate gross proceeds of $13.8 million. The Company received approximately $12.5 million in net proceeds after deducting underwriting discounts and commissions and other estimated offering expenses payable by us. The Company also issued to the selling agent warrants to purchase in aggregate 60,000 shares of common stock with an exercise price of $7.50. The warrants were valued at $223,500 and expire on May 15, 2024.
 
In the three and nine months ended June 30, 2018:
 
On November 17, 2017, the Company completed an IPO of 2,000,000 shares of its common stock for aggregate gross proceeds of $12.0 million.
 
 
30
 
 
In November 2017, we issued 6,667 shares of our common stock to an individual as part of a consulting agreement. The shares were valued at $37,002, based on the trading price upon issuance and expensed as contract compensation.
 
In January 2018, we issued 230,000 shares of our common stock, which were granted as restricted stock awards on October 1, 2016 to board members. The restricted stock awards vested on January 1, 2018. The shares were valued at fair market value upon issuance at $195,500 and amortized over the vesting period and expensed as stock compensation.
 
In March 2018, we issued 5,000 shares of our common stock to an investor relations firm for services. The shares were valued at $20,000, based on the trading price upon issuance, and is being amortized and expensed as professional services over the service period ending June 2018.
 
In May 2018, we issued 60,000 shares of our common stock to an investment banking firm for general financial advisory and investment banking services. The shares were valued at $303,000, based on the trading price upon issuance, and is being amortized and expensed as professional services over the service period ending April 2019.
 
In June 2018, we issued 25,000 shares of our common stock to a broker dealer for business advisory services. The shares were valued at $118,000, based on the trading price upon issuance, and is being amortized and expensed as professional services over the service period ending December 2019.
 
Stock option transactions:
 
In the three and nine months ended June 30, 2019:
 
In May 2019 we granted per the annual board compensation plan, an aggregate of 120,000 common stock options to six independent directors. The options vest immediately, have an exercise price of $5.41 per share and a term of ten years. We have recorded an expense for the options of $562,440 for the three and nine months ending June 30, 2019.
 
In May 2019 we granted an aggregate of 610,000 common stock options to twelve employees. The options vary in amounts issued and vesting tiers, which include no vesting with an exercise price of $6.40, vesting at May 15, 2020 with an exercise price of $7.00, vesting at May 15, 2021 with an exercise price of $7.50, and vesting at May 15, 2022 with an exercise price of $7.50. The options have a term of ten years. We have recorded an expense for the options of $1,290,732 for the three and nine months ended June 30, 2019.
 
In the three and nine months ended June 30, 2018:
 
On May 14, 2018 we granted an aggregate of 50,000 common stock options to an employee. The options vest 50% November 14, 2018 and 50% May 14, 2019. The options have an exercise price of $5.27 per share and a term of seven years. We have recorded an expense for the options of $38,950 for the three and nine months ended June 30, 2018.
 
On May 29, 2018 we granted an aggregate of 150,000 common stock options to an employee. The options vest 50% immediately and 50% January 1, 2019. The options have an exercise price of $4.78 per share and a term of ten years. We have recorded an expense for the options of $302,750 for the three and nine months ended June 30, 2018.
 
The following table summarizes the inputs used for the Black-Scholes pricing model on the options issued in the nine months ended June 30, 2019 and 2018:
 
 
2019 
 
2018
Exercise price
$5.41 – $7.50